Evidence mapPaperPMID 42077406Full record

ArticleInfection and drug resistance2026

Epidemiology, Risk Factors, and Routine Blood Biomarkers of Aspergillosis in Cancer Patients in Jiangxi, China.

Hazrat Bilal, Xunsong Wang, Jiamei Yu, Yan Li, Xiaohui Li, Hanman Qiu, Muhammad Nadeem Khan, Rahat Ullah Khan, Muhammad Shafiq, Qiao-Li Lv and 1 more

Abstract read
In one paragraph

Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hazrat BilalJiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, People's Republic of China.ORCID 0000-0002-9679-3054
Xunsong WangDepartment of Medical Laboratory, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, Jiangxi, 330029, People's Republic of China.
Jiamei YuJiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, People's Republic of China.
Yan LiJiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, People's Republic of China.
Xiaohui LiJiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, People's Republic of China.
Hanman QiuJiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, People's Republic of China.
Muhammad Nadeem KhanDepartment of Cell Biology and Genetics, Shantou University Medical College, Shantou, Guangdong, 515041, People's Republic of China.
Rahat Ullah KhanCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing, 101408, People's Republic of China.
Muhammad ShafiqResearch Institute of Clinical Pharmacy, Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, 515041, People's Republic of China.ORCID 0000-0002-4346-5903
Qiao-Li LvJiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, People's Republic of China.
Bin XuJiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Aspergillosis is a serious public health concern worldwide; however, its epidemiology and clinical predictors remain poorly characterized among cancer patients in China, particularly in regions such as Jiangxi, where regional data are limited. This study aimed to evaluate the epidemiology, risk factors, and potential utility of routine inflammatory biomarkers in distinguishing Methods: In the current retrospective study, the epidemiology, risk factors, and blood biomarkers of Results: There were 354 cases in all, with 14.1% colonization, 43.5% possible infections, and 42.4% probable infections. Almost half of the patients had underlying lung cancer (n = 161, 45.48%), and Conclusion: This study provides comprehensive epidemiological data on aspergillosis in a large cohort of cancer patients in Jiangxi, China, and highlights the potential value of routinely available inflammatory markers in differentiating colonization from infection. These findings may support early risk stratification and improve clinical decision-making, particularly in resource-limited settings where advanced fungal diagnostics are not readily available.

Indexed as

cancer patientscolonizationinflammatory biomarkersinvasive aspergillosisrisk factors

Identifiers

PMID42077406
PMCPMC13135037

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.